Calidi Biotherapeutics Taps Biotech Veteran Eric Poma as New CEO to Drive Clinical Growth

Calidi Biotherapeutics has appointed Eric Poma, Ph.D., as its new Chief Executive Officer, marking a strategic leadership transition aimed at propelling the company's oncology research and development efforts forward. Poma will take the helm effective April 22, succeeding Allan Camaisa, who will continue to serve on the company's Board of Directors.

With over 30 years of experience in the biotechnology sector, Poma brings substantial leadership credentials to the role. His previous leadership at Molecular Templates demonstrated his ability to drive significant financial and strategic outcomes, including raising over $250 million and establishing critical partnerships with major pharmaceutical companies such as Takeda, Vertex, and Bristol Myers Squibb.

The leadership change comes at a pivotal moment for Calidi Biotherapeutics, which is preparing to advance its systemic virotherapy platform. The company is specifically focused on developing innovative stem cell-based technologies designed to combat cancer by empowering the immune system through unique cell delivery platforms.

Poma's appointment signals the company's commitment to progressing its clinical development strategy, particularly as it prepares for a dose-escalation trial of CLD-201 targeting solid tumors. His extensive background in biotech leadership positions Calidi to potentially accelerate its research and bring transformative cancer therapies closer to clinical application.

The company's proprietary technology centers on utilizing potent allogeneic stem cells capable of carrying oncolytic viruses. This approach offers a promising dual strategy for potentially treating and preventing metastatic disease across multiple oncology indications, including high-grade gliomas and solid tumors.

For human resources professionals and business leaders in the biotechnology sector, this leadership transition underscores the critical role of strategic executive recruitment in driving innovative medical research. The appointment of an experienced industry veteran like Poma demonstrates how targeted leadership can potentially accelerate a company's clinical development and strategic objectives.